68506-86-5
68506-86-5 結(jié)構(gòu)式
基本信息
4-氨基己-5-烯酸
(+/-)-Vigabatrin
SABRIL
Γ-VINYL-GABA
5-Hexenoic acid, 4-amino-
(±)-4-aminohex-5-enoic acid
Vigabatrin, racemic mixture
rac-VigabatrinDiscontinued See V253010
Vigabatrin hydrochloride salt, racemic mixture
物理化學(xué)性質(zhì)
pharmaceutical small molecule
安全數(shù)據(jù)
toxic compounds or compounds which causing chronic effects
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2026/06/05 | HY-15399R | 4-氨基己-5-烯酸 Vigabatrin (Standard) | 68506-86-5 | 5 mg | 1250元 |
| 2026/06/05 | HY-15399R | 4-氨基己-5-烯酸 Vigabatrin (Standard) | 68506-86-5 | 10 mg | 2000元 |
| 2026/06/05 | HY-15399R | 4-氨基己-5-烯酸 Vigabatrin (Standard) | 68506-86-5 | 25 mg | 4000元 |
常見問題列表
A significant increase in seizure threshold is observed following systemic (i.p.) administration of high (600 or 1200 mg/kg) doses of Vigabatrin. Bilateral microinjection of Vigabatrin (10 μg) into either the anterior or posterior substantia nigra pars reticulata (SNr) also increased seizure threshold, but less markedly than systemic treatment. Focal delivery into the subthalamic nucleus (STN) increased seizure threshold more markedly than either intranigral or systemic administration of Vigabatrin.
Vigabatrin inhibits the uptake of taurine in Caco-2 and MDCK cells to 34% and 53%, respectively, at a concentration of 30 mM. In Caco-2 cells the uptake of Vigabatrin under neutral pH conditions is concentration-dependent and saturable with a Km-value of 27 mM. Vigabatrin is able to inhibit the uptake of taurine in intestinal and renal cell culture models.